SBBP

Strongbridge Biopharma plc [SBBP] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SBBP Stock Summary

In the News

04:05 28 Mar 2024 SBBP

Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdin

04:01 28 Mar 2024 SBBP

Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act").

04:01 28 Mar 2024 SBBP

Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the “Court”) has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (“Xeris”) by means of scheme of arrangement (the “Scheme”) under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Act”).

04:01 28 Mar 2024 SBBP

Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (“Xeris”). As described below, at least 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the “Court Meeting”) and at an extraordinary general meeting of shareholders (the “EGM”) were in favor of the transaction, representing (in each case) approximately 67 percent of the shares outstanding and eligible to be voted at each of the Strongbridge shareholder meetings held on September 8, 2021 in Pennsylvania, United States of America. Upon close of the transaction, the business of Xeris and Strongbridge will be combined under an entity called Xeris Biopharma Holdings, Inc. (“Xeris Biopharma Holdings” or “HoldCo”).

07:30 28 Mar 2024 SBBP

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris

07:30 28 Mar 2024 SBBP

Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals

10:39 28 Mar 2024 SBBP

Strongbridge Biopharma (SBBP) Reports Q2 Loss, Tops Revenue Estimates

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

07:30 28 Mar 2024 SBBP

Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update

~ Reports KEVEYIS ®  (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~

07:30 28 Mar 2024 SBBP

Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement

DUBLIN, Ireland and TREVOSE, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the “Irish Takeover Rules”), that the definitive joint proxy statement/prospectus of Strongbridge (the “Proxy Statement”), which also constitutes a scheme circular under Irish law, is being sent as of July 30, 2021 to Strongbridge shareholders.

08:15 28 Mar 2024 SBBP

Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced in accordance with Rule 2.10 of the Irish Takeover Rules that, as of the close of business on July 28, 2021, Strongbridge's issued share capital, excluding treasury shares, is comprised of 67,828,952 ordinary shares with a par value of $0.01 per share. Strongbridge's ordinary shares are traded on the Nasdaq under the symbol SBBP. The International Securities Identification Number (ISIN) of the Strongbridge ordinary shares is IE00BYZ5XL97.

SBBP Financial details

Company Rating
Neutral
Market Cap
0
Income
-40.16M
Revenue
34.72M
Book val./share
0.66
Cash/share
0.94
Dividend
-
Dividend %
-
Employees
72
Optionable
No
Shortable
Yes
Earnings
05 Aug 2021
P/E
-2.49
Forward P/E
-
PEG
0.91
P/S
-
P/B
1.71
P/C
2.13
P/FCF
-
Quick Ratio
4.27
Current Ratio
4.37
Debt / Equity
0.41
LT Debt / Equity
0.38
-
-
EPS (TTM)
-0.65
EPS next Y
-
EPS next Q
-
EPS this Y
-10.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
19.8%
EPS Q/Q
11.11%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
50.34%
Inst Trans
0.97%
ROA
-37%
ROE
-65%
ROC
-0.43%
Gross Margin
93%
Oper. Margin
-140%
Profit Margin
-147%
Payout
-
Shs Outstand
67.77M
Shs Float
38.86M
-
-
-
-
Target Price
-
52W Range
1.96-2.05
52W High
0%
52W Low
+100%
RSI
-
Rel Volume
2.16
Avg Volume
316.35K
Volume
684.68K
Perf Week
0%
Perf Month
0%
Perf Quarter
0%
Perf Half Y
0%
-
-
-
-
Beta
1.59577
-
-
Volatility
0%, 0%
Prev Close
0%
Price
2
Change
2.04%

SBBP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2020-12-31

Metric History 2016-12-312017-12-312018-12-312019-12-31 2020-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.190.360.390.55
Net income per share
-2.26-3.110.64-0.89-0.8
Operating cash flow per share
-1.47-1.24-1.7-0.81-0.68
Free cash flow per share
-1.47-1.24-1.71-0.81-0.68
Cash per share
3.11.572.461.411.56
Book value per share
3.11-0.332.271.31.17
Tangible book value per share
-0.05-1.491.520.720.68
Share holders equity per share
3.11-0.332.271.31.17
Interest debt per share
0.861.150.2500.33
Market cap
51.72M264.95M222.77M115.75M136.34M
Enterprise value
3.32M245.23M100.28M60.17M67.01M
P/E ratio
-1.06-2.336.99-2.34-3.02
Price to sales ratio
037.612.365.334.44
POCF ratio
-1.63-5.84-2.63-2.58-3.58
PFCF ratio
-1.63-5.84-2.62-2.58-3.57
P/B Ratio
0.77-22.241.971.62.08
PTB ratio
0.77-22.241.971.62.08
EV to sales
034.85.562.772.18
Enterprise value over EBITDA
-0.06-2.41.92-1.41-1.73
EV to operating cash flow
-0.1-5.41-1.19-1.34-1.76
EV to free cash flow
-0.1-5.41-1.18-1.34-1.76
Earnings yield
-0.94-0.430.14-0.43-0.33
Free cash flow yield
-0.61-0.17-0.38-0.39-0.28
Debt to equity
0.28-3.17000.26
Debt to assets
0.130.36000.14
Net debt to EBITDA
0.950.19-2.351.311.79
Current ratio
4.244.877.673.444.37
Interest coverage
-1.74K-12.29-6.550-32.31
Income quality
0.650.4-2.660.910.85
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
05.153.512.111.33
Research and developement to revenue
02.451.411.420.84
Intangibles to total assets
0.50.410.220.280.23
Capex to operating cash flow
00000
Capex to revenue
00-0.0200
Capex to depreciation
00-0.05-0.010
Stock based compensation to revenue
00.730.430.40.24
Graham number
12.564.775.725.124.6
ROIC
-0.39-2.08-0.71-0.9-0.51
Return on tangible assets
-0.7-1.840.24-0.58-0.48
Graham Net
-0.15-1.561.370.640.62
Working capital
51.64M48.33M115.05M59.25M71.22M
Tangible asset value
-1.18M-54.33M75.57M39.83M38.26M
Net current asset value
-2.96M-55.03M74.97M38.1M36.86M
Invested capital
0.28-3.17000.26
Average receivables
382K1.17M1.61M1.96M2.55M
Average payables
1.94M1.17M1.22M2.26M2.41M
Average inventory
0255.5K2.23M2.97M1.55M
Days sales outstanding
082.0632.9238.4833.27
Days payables outstanding
0306.92108.42318.11244.71
Days of inventory on hand
0125.77361.34190.33182
Receivables turnover
04.4511.099.4910.97
Payables turnover
01.193.371.151.49
Inventory turnover
02.91.011.922.01
ROE
-0.739.530.28-0.69-0.69
Capex per share
00-0.0100

Quarterly Fundamentals Overview

Last date of statement is 2021-06-30 for Q2

Metric History 2020-06-302020-09-302020-12-312021-03-31 2021-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.140.140.150.120.15
Net income per share
-0.32-0.06-0.21-0.18-0.2
Operating cash flow per share
-0.22-0.1-0.09-0.2-0.15
Free cash flow per share
-0.22-0.1-0.09-0.2-0.15
Cash per share
1.11.461.561.10.94
Book value per share
0.881.331.170.830.66
Tangible book value per share
0.330.820.680.440.29
Share holders equity per share
0.881.331.170.830.66
Interest debt per share
0.130.140.320.280.28
Market cap
205.26M117.82M136.34M185.96M200.93M
Enterprise value
152.36M43.71M66.09M129.88M155.3M
P/E ratio
-2.97-9.32-2.85-3.94-3.79
Price to sales ratio
26.4514.616.5722.1920.01
POCF ratio
-16.91-20.46-27.27-13.88-20.45
PFCF ratio
-16.91-20.42-27.27-13.87-20.45
P/B Ratio
4.291.582.083.334.53
PTB ratio
4.291.582.083.334.53
EV to sales
19.635.428.0315.515.47
Enterprise value over EBITDA
-9.68-32.14-6.53-13.31-13.92
EV to operating cash flow
-12.56-7.59-13.22-9.7-15.8
EV to free cash flow
-12.56-7.58-13.22-9.69-15.8
Earnings yield
-0.08-0.03-0.09-0.06-0.07
Free cash flow yield
-0.06-0.05-0.04-0.07-0.05
Debt to equity
0.150.10.260.320.41
Debt to assets
0.070.060.140.160.19
Net debt to EBITDA
3.3654.56.945.754.09
Current ratio
3.394.514.373.633
Interest coverage
-38.25-18.33-18.57-12.88-16.13
Income quality
0.71.820.421.130.74
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.241.141.411.311.59
Research and developement to revenue
0.790.840.650.70.54
Intangibles to total assets
0.310.240.230.240.26
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
0-0.010-0.010
Stock based compensation to revenue
0.230.260.220.270.21
Graham number
2.511.32.371.811.7
ROIC
-0.1-0.37-0.12-0.12-0.21
Return on tangible assets
-0.25-0.04-0.13-0.14-0.18
Graham Net
0.240.740.620.360.22
Working capital
46.54M68M71.22M57.69M46.74M
Tangible asset value
18.01M45.97M38.26M29.76M19.56M
Net current asset value
16.26M44.28M36.86M27.46M17.69M
Invested capital
0.150.10.260.320.41
Average receivables
2.79M2.89M2.85M2.82M3.21M
Average payables
3.62M1.77M1.54M3.61M3.19M
Average inventory
1.33M1.22M1.11M1.06M1.05M
Days sales outstanding
33.4632.2830.6530.5632.09
Days payables outstanding
448.17350.29301.971.26K122.38
Days of inventory on hand
301.15246.18224.59220.51212.18
Receivables turnover
2.692.792.942.952.8
Payables turnover
0.20.260.30.070.74
Inventory turnover
0.30.370.40.410.42
ROE
-0.36-0.04-0.18-0.21-0.3
Capex per share
00000

SBBP Frequently Asked Questions

What is Strongbridge Biopharma plc stock symbol ?

Strongbridge Biopharma plc is a US stock , located in Trevose of Pennsylvania and trading under the symbol SBBP

What is Strongbridge Biopharma plc stock quote today ?

Strongbridge Biopharma plc stock price is $2 today.

Is Strongbridge Biopharma plc stock public?

Yes, Strongbridge Biopharma plc is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Same Price Range
Similar Market Cap